Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Justin Doan"'
Autor:
Imtiaz A Samjoo, Alexandra Hall, Connie Chen, Bao-Ngoc Nguye, Meaghan Bartlett, Mary Lou Smith, Nadia Harbeck, Joseph C Cappelleri, Meghan Karuturi, Doris Makari, Lillian Shahied Arruda, Rickard Sandin, Kent Hanson, Justin Doan
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 13, Iss 10 (2024)
Aim: To evaluate the impact of palbociclib treatment on health-related quality of life (HRQoL) in patients with hormone receptor-positive, human epidermal growth factor 2-negative advanced breast cancer (HR+/HER2- aBC) or metastatic breast cancer (
Externí odkaz:
https://doaj.org/article/f6f1b3a08af445aab4c5bd48f8bb6817
Publikováno v:
BMC Urology, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background Advances in systemic targeted therapies afford treatment opportunities in patients with metastatic renal cell carcinoma (RCC). Elderly patients with metastatic RCC present a subpopulation for consideration owing to competing cause
Externí odkaz:
https://doaj.org/article/2968ae3fb4374235b32d1301c7acb103
Publikováno v:
Experimental Hematology & Oncology, Vol 7, Iss 1, Pp 1-11 (2018)
Abstract Background We evaluated the cost-effectiveness of nivolumab versus everolimus in patients with advanced renal cell carcinoma (RCC) from a US payer perspective. Methods A partitioned survival model consisting of three health states, progressi
Externí odkaz:
https://doaj.org/article/1df5e660f8bd4b3391bf604100d0b086
Autor:
Baris Deniz, Apoorva Ambavane, Shuo Yang, Arman Altincatal, Justin Doan, Sumati Rao, M Dror Michaelson
Publikováno v:
PLoS ONE, Vol 14, Iss 8, p e0215761 (2019)
ObjectiveAdvanced renal cell carcinoma (RCC) is commonly treated with vascular endothelial growth factor or mammalian target of rapamycin inhibitors. As new therapies emerge, interest grows in gaining a deeper understanding of treatment sequences. Re
Externí odkaz:
https://doaj.org/article/d41050ae8b2f4430b56acacde5d9c9ce
Autor:
Baris Deniz, Arman Altincatal, Apoorva Ambavane, Sumati Rao, Justin Doan, Bill Malcolm, M Dror Michaelson, Shuo Yang
Publikováno v:
PLoS ONE, Vol 13, Iss 8, p e0203406 (2018)
OBJECTIVE:In oncology, extrapolation of clinical outcomes beyond trial duration is traditionally achieved by parametric survival analysis using population-level outcomes. This approach may not fully capture the benefit/risk profile of immunotherapies
Externí odkaz:
https://doaj.org/article/3485163a5e8243b6af12d64d4c95953c
Autor:
Mark D. Danese, Karla Lindquist, Justin Doan, Deepa Lalla, Melissa Brammer, Robert I. Griffiths
Publikováno v:
Journal of Cancer Epidemiology, Vol 2012 (2012)
Background. Trastuzumab improves survival in HER2-positive women with metastatic breast cancer (MBC). The consequences of longer survival include a higher likelihood of additional metastases, including those in the central nervous system (CNS). The e
Externí odkaz:
https://doaj.org/article/70c3efa219b14a628a2b56c4aef6b978
Autor:
Neil Iyengar, Clay Williams, Michael Rogan, Laurie Campbell, Shirley Mertz, Jeremy Block, Maria Ebling, Connie Chen, Justin Doan, Samantha K. Kurosky, Timothy Pluard
Publikováno v:
Journal of the National Comprehensive Cancer Network. 20:HSR22-147
Publikováno v:
BMC Urology
BMC Urology, Vol 19, Iss 1, Pp 1-9 (2019)
BMC Urology, Vol 19, Iss 1, Pp 1-9 (2019)
486 Background: Although there have been significant advances in the detection and treatment of renal cell carcinoma (RCC), many elderly patients—particularly those with stage IV disease—likely receive no treatment. The purpose of this research w
Autor:
J. Ross Maclean, Michael Neely, Justin Doan, Jacquelyn W Chou, Jason Shafrin, Jeffrey Sullivan
Publikováno v:
Cancer Management and Research
Jason Shafrin,1 Jeffrey Sullivan,1 Jacquelyn W Chou,1 Michael N Neely,2 Justin F Doan,3 J Ross Maclean1 1Precision Health Economics, LosAngeles, CA, USA; 2Department of Pediatrics, Keck School of Medicine, University of Southern California, LosAngele
Autor:
Linlin Luo, David Cella, Caitlyn T. Solem, Ruchitbhai Shah, Justin Doan, Marc F. Botteman, Robert J. Motzer
Publikováno v:
Clinical genitourinary cancer
This study assessed the net health benefits of treatment with nivolumab versus everolimus among patients with advanced renal cell carcinoma by assessing the quality (ie, patient preferences) and quantity of survival (ie, time spent with significant t